Clinical Trial Update: The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating psilocybin for safety and efficacy in treatment-resistant depression with chronic suicidal ideation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Suicidal Ideation
• Treatment-resistant Depression

Drugs mentioned

• Psilocybin (psilocybin)

Snippet

Sponsor: Sheppard Pratt Health System | Conditions: Treatment Resistant Depression, Suicidal Ideation | Phase 2 | Status: COMPLETED